(Juhi Aishwary, Journalist)
New Delhi: The Council for Scientific and Industrial Research (CSIR) has received approval from the Drug Controller General of India (DGCI) for clinical trials of two drugs – favipiravir and phytopharmaceutical – to compete with Kovid-19.
Clinical trial of these drugs will begin within a week
Favipiravir drug is commonly used in the treatment of influenza in Japan, China, and some other countries. CSIR is searching for a biological drug in the form of phytopharmaceutical, which has already been found successful in treating dengue. Its effect against Kovid-19 is now being investigated. CSIR Director General Shekhar Mande said that they would start clinical trials of these drugs within a week. He said that CSIR is working with many well-known pharmaceutical companies. He is trying to see if Kovid can bring a definitive solution against the -19. In this regard, clinical trials were started with some companies last night.
Human monoclonal antibodies approved treatment of Covid-19
The Council of Scientific and Industrial Research (CSIR) has approved a project to develop human monoclonal antibodies as a treatment for Covid-19. The project is being led by leading vaccine and biomedical manufacturer Bharat Biotech. The aim is to generate highly effective and specific human monoclonal antibodies by alternative therapies, which are capable of neutralizing the SARS-COV-2 virus.
It will bring together the National Center for Cell Science-Pune, Indian Institute of Technology-Indore, Predomics Technologies-Gurgaon, and Bharat Biotech during public health emergencies. The point of vaccination is to look after health from future infections, said Dr. Krishna Ella, chairman, and director of Bharat Biotech. It might not be able to provide a complete solution alone.